COVID-19 News & Resource Center
[vc_row][vc_column][vc_column_text]EPI Health has graciously supported the COVID-19 News and Resource Center.
COVID-19 DERM TOPICS
COVID-19 Peer-reviewed Articles
Safely Reopening Derm Practices Video Series
JDD COVID-19 Webinar Series
COVID-19: Urgent Medical and Aesthetic Issues for Dermatology
Streamed live on April 1st, 2020, and now available to watch on-demand, this webinar panel provi …
[vc_row][vc_column][vc_column_text]EPI Health has graciously supported the COVID-19 News and Resource Center.
COVID-19 DERM TOPICS
COVID-19 Peer-reviewed Articles
Safely Reopening Derm Practices Video Series
JDD COVID-19 Webinar Series
COVID-19: Urgent Medical and Aesthetic Issues for Dermatology
Streamed live on April 1st, 2020, and now available to watch on-demand, this webinar panel provi … 
With the advent of biologics, patients with moderate-to-severe plaque psoriasis have experienced increased control of disease and improved quality of life. Tumor necrosis factor (TNF) inhibitors are some of the earliest biologics prescribed for psoriasis, psoriatic arthritis and, more recently, hidradenitis suppurativa. In this month’s installment of Therapeutic Cheat Sheets, we discuss TNF inhi … 
In this month’s installment of Therapeutic Cheat Sheet, we will review methotrexate and its use in dermatology. Methotrexate has been utilized as therapy for psoriasis and many other dermatologic conditions since its approval by the FDA in 1972.1 While an effective systemic agent for a multitude of dermatologic and non-dermatologic diseases, prescribers should be aware of the side effect profile … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. Jonathan Zippin, Vice-Chair of Research and an Associate Attending Dermatologist and Associate Professor of Dermatology at Weill Medical College of Cornell, and Director of the Contact, Occupational and Photodermatitis Service. Watch as he reviews the JAK/STAT signaling pathway in normal i … 
So many diseases, so few FDA approved indications. Between the mind-numbing time and cost from bench to bottle, it is no surprise that dermatologists, as masters of the integument are the off-label bandits, marrying their wealth of knowledge on the pathophysiology of skin diseases to the mechanisms by which medications work to create an evidenced-based armament of therapies for both common and rar …